Search

Novartis AG

Lezárt

152.19 -0.97

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

152.66

Maximum

153.77

Fő mutatók

By Trading Economics

Bevétel

110M

3.3B

Értékesítés

894M

14B

P/E

Szektor átlag

23.979

57.366

Egy részvényre jutó nyereség

2.41

Osztalékhozam

2.98

Profit margin

22.654

Munkavállalók

75,267

EBITDA

526M

5.9B

Ajánlások

By TipRanks

Ajánlások

Semleges

12 hónapos előrejelzés

+3.37% upside

Osztalékok

By Acuity

Osztalékhozam

Szektor átlag

2.98%

2.16%

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

15B

300B

Előző nyitás

153.16

Előző zárás

152.19

Novartis AG Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 29. 23:51 UTC

"Bitcoin and Ethereum Rise Amid Market Uncertainty; Barclays Warns of Commodity Shock, Fed Signals Possible Rate Hikes, and Canada's GDP Growth Falls Short of Expectations."

2026. aug. 29. 23:51 UTC

Bitcoin and Ethereum rise amid economic uncertainties, while Barclays warns of a commodity shock and Fed Chair hints at potential interest rate hikes.

2026. aug. 29. 23:51 UTC

Cryptocurrency gains amid economic uncertainty; Barclays warns of commodity shock from El Niño, while Fed signals potential rate hikes and Canada faces trade tensions.

2026. aug. 29. 23:51 UTC

Cryptocurrency gains amid economic uncertainty, while Barclays warns of commodity shocks and Fed signals potential rate hikes, impacting U.S. stock markets and Canadian trade tensions.

2026. aug. 29. 23:41 UTC

U.S. Import Data Release on September 3, 2026 Expected to Reflect Impact of Tariff Changes Amid Escalating Trade Tensions with Canada.

2026. aug. 29. 23:41 UTC

U.S. Trade Deficit Expected to Widen to $86.4 Billion Amid Ongoing Tariff Tensions with Canada

2026. aug. 29. 23:41 UTC

Mexican Business Confidence Remains Low Ahead of September Survey, Anticipating Continued Economic Challenges

2026. aug. 29. 23:41 UTC

U.S. July 2026 export data release on September 3 expected to reflect ongoing trade challenges amid U.S.-Canada tariff tensions, raising market volatility concerns.

2026. aug. 29. 23:41 UTC

Canada's Balance of Trade Expected to Show C$3.2 Billion Surplus Amid Rising U.S.-Canada Tariff Tensions

2026. aug. 29. 23:31 UTC

Brazil's Q2 2026 GDP Growth Rate Release on September 1st Sparks Cautious Optimism Amid Economic Challenges and Global Trade Tensions.

2026. aug. 29. 23:31 UTC

South Africa's Balance of Trade report on August 31 expected to reveal if trade surplus continues amid concerns over El Niño impacts and global commodity markets.

2026. aug. 29. 23:11 UTC

ADP Employment Change report on September 2 forecasts a modest increase of 47,000 jobs amid cautious labor market sentiment and potential downward revisions in nonfarm payrolls.

2026. aug. 29. 23:11 UTC

Mexican Consumer Confidence Index Set for Release on September 3, Amid Global Economic Uncertainty and Mixed Sentiments.

2026. aug. 29. 23:01 UTC

Macro News

DAX 30 Index declines in after-market hours, pressured by hawkish Fed remarks and geopolitical tensions. The index remains near its one-month low.

2026. aug. 29. 22:52 UTC

Japan's Household Spending Data Release Sparks Caution Amid Rising Inflation Concerns and Weak Investor Confidence

2026. aug. 29. 22:52 UTC

Japan's Household Spending Expected to Decline by -1.6% YoY Amid Inflation Concerns and Weak Consumer Sentiment

2026. aug. 29. 22:52 UTC

Brazil's Q2 GDP Growth Rate Release on September 1, 2026, Sparks Cautious Market Anticipation Amid Global Economic Uncertainties.

2026. aug. 29. 22:51 UTC

Correlated Moves

Barclays reports a potential commodity shock from adverse weather and underinvestment. In after-market trading, Silver Ounce vs Euro is roughly flat near its one-month range.

2026. aug. 29. 22:41 UTC

Upcoming MBA Mortgage Rate Release Sparks Cautious Investor Sentiment Amid Inflation and Fed Hike Expectations

2026. aug. 29. 22:11 UTC

Germany's Inflation Rate Expected to Rise to 2.9% in August Amid Fed Concerns Over Elevated Prices

2026. aug. 29. 22:11 UTC

Germany's Inflation Rate Release on August 31 Sparks Investor Caution Amid Persistent Price Pressures and Potential Monetary Policy Tightening.

2026. aug. 29. 22:11 UTC

Japan's Q2 2026 Capital Spending YoY data set for release, with a modest growth forecast of 0.2% amid cautious investor sentiment and rising inflation concerns.

2026. aug. 29. 21:51 UTC

Japan's Industrial Production Expected to Contract 0.006% in July Amid Mixed Economic Sentiment and Rising Inflation Concerns

2026. aug. 29. 21:51 UTC

Japan's Retail Sales YoY data for July 2026 expected to rise by 0.3% amid mixed economic signals and wavering investor confidence ahead of the release on August 30, 2026.

2026. aug. 29. 21:41 UTC

South Africa's Business Confidence Index set for release amid cautious market sentiment following significant declines and ongoing geopolitical uncertainties.

2026. aug. 29. 21:41 UTC

Australia's Ai Group Industry Index set for release on September 1, 2026, amid cautious expectations of continued industrial contraction due to high costs and subdued demand.

2026. aug. 29. 21:41 UTC

South Korea's Upcoming Inflation Rate Release on September 1, 2026, Expected to Impact Economic Outlook Amid Mixed Market Sentiment and Global Price Pressures.

2026. aug. 29. 21:31 UTC

API Crude Oil Stock Change Data Release on September 1, 2026, Expected to Impact U.S. Market Amid Rising Inventories and Geopolitical Tensions

2026. aug. 29. 20:41 UTC

India's Q2 2026 GDP Growth Rate Forecast at 7.1% Amid Cautious Optimism and Global Economic Pressures

2026. aug. 29. 20:31 UTC

Euro Area Retail Sales Expected to Rise 0.3% in July Amid Mixed Economic Signals and Caution from Spain's Decline

Társak összehasonlítása

Árváltozás

Novartis AG Előrejelzés

Célár

By TipRanks

3.37% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 159 USD  3.37%

Magas 180 USD

Alacsony 139 USD

5 Wall Street elemző 12 hónapos célárain alapulva a(z)Novartis AG termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Semleges

5 ratings

2

Vétel

2

Tartás

1

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
help-icon Live chat